查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870714

抗逆轉錄病毒藥物市場按產品類型、給藥途徑、劑型、最終用戶、通路、治療方案和病患小組分類－2025-2032年全球預測

Anti-Retroviral Drugs Market by Product Type, Route Of Administration, Formulation, End User, Distribution Channel, Therapy Line, Patient Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗逆轉錄病毒藥物市場規模將達到 421.3 億美元，年複合成長率為 4.75%。

關鍵市場統計數據
基準年 2024 290.5億美元
預計年份：2025年 304.4億美元
預測年份 2032 421.3億美元
複合年成長率 (%) 4.75%

對影響抗逆轉錄病毒療法臨床開發和商業性化實施的進展、衛生系統壓力和實際優先事項進行策略概述

要了解抗逆轉錄病毒療法的現狀，需要從兩個觀點：臨床進展和計畫實施。過去十年，藥物技術的逐步改進使抗逆轉錄病毒療法從複雜的多藥物聯合聯合治療轉變為簡化的聯合治療和長效製劑，從而重塑了患者的依從性模式和臨床療效。同時，醫療系統和支付方正在調整採購、分發和報銷模式，以應對慢性病治療的需求，同時確保不同患者群體都能獲得可及且負擔得起的治療。這種現狀需要策略整合，將治療創新與實際營運結合。

推動抗逆轉濾病毒治療創新和醫療系統採用的重大科學、供應和商業轉折點

抗逆轉濾病毒治療領域正經歷著變革性的轉變，其影響範圍不僅限於分子創新，也涵蓋給藥方案、診斷技術和服務設計等各個面向。在治療方面，整合酶鏈轉移抑制劑的成熟和聯合治療的策略性應用正在重新定義療效標準，而對長效注射劑研發的重新關注正在改變患者的依從性預期和治療路徑。這些臨床轉變與診斷技術日益融入治療流程同步發生，因此能夠更早發現抗藥性並制定更精準的治療方案轉換策略。

不斷變化的關稅制度和貿易措施如何影響抗逆轉錄病毒療法的供應鏈策略、製造地和採購決策

關稅和貿易措施的實施將對整個抗逆轉錄病毒供應鏈產生連鎖反應，從原料藥的採購到成品製劑的組裝和分銷，無一倖免。當進口原料被徵收關稅時，製造商通常面臨更高的單位生產成本，這會影響最終製劑和包裝工序的位置決策。為此，一些公司加快了在更靠近終端市場的產能投資，而另一些公司則試圖透過與供應商重新談判合約條款或提高垂直整合度來減輕跨境課稅的影響。

提供全面的細分資訊，並詳細分析產品類型、給藥途徑、製劑亞型、臨床環境、配銷通路、治療線和病患小組如何影響戰略決策。

觀點產品類型、給藥途徑、製劑特性、終端用戶環境、分銷管道、治療定位和病患小組角度分析市場，可以發現不同的商業性和臨床意義。基於產品類型，每種治療類別——Ccr5拮抗劑、融合抑制劑、整合酶鏈轉移抑制劑、非核苷類逆轉錄酶抑制劑、核苷類逆轉錄酶抑制劑和蛋白酶抑制劑——都具有其獨特的抗藥性特徵、聯合用藥潛力和安全性考量，這些因素會影響藥物選擇標準的優先順序和臨床治療順序。基於給藥途徑，口服和腸外給藥之間的差異導致了不同的藥物支持模式、給藥部位要求以及醫護人員在注射長效藥物時所需的培訓。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 長效注射型抗逆轉錄病毒療法的出現提高了患者的依從性。
  • 增加雙藥維持治療的採用，以降低長期毒性風險
  • 非專利諾福韋艾拉酚胺製劑的快速普及降低了治療成本。
  • 將數位化藥物依從性監測平台整合到愛滋病照護計畫中
  • 透過擴大兒童抗逆轉錄病毒藥物劑量指引來改善兒童治療效果
  • 用於治療愛滋病毒的廣譜中和抗體療法的研發仍在繼續。
  • 監管部門的核准正在推動基於比克替拉韋的單藥組合藥物的市場應用。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的抗逆轉錄病毒病毒藥物市場

  • CCR5拮抗劑
  • 融合抑制劑
  • 整合酶鏈轉移抑制劑
  • 非核苷類逆轉錄酶抑制劑
  • 核苷類逆轉錄酶抑制劑
  • 蛋白酶抑制劑

第9章 依給藥途徑分類的抗逆轉錄病毒病毒藥物市場

  • 口服
  • 腸外

第10章抗逆轉錄病毒藥物市場（依劑型分類）

  • 注射
    • 靜脈注射
    • 皮下注射
  • 口服液
    • 解決方案
    • 暫停
  • 口服固態劑型
    • 膠囊
    • 藥片

抗逆轉錄病毒病毒藥物市場

  • 居家醫療
  • 醫院
  • 專科診所

第12章抗逆轉錄病毒藥物市場（依分銷管道分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 依治療類別分類的抗逆轉錄病毒藥物市場

  • 一線治療
  • 補救性治療
  • 二線治療

第14章 按病患小組的抗逆轉錄病毒病毒藥物市場

  • 成人版
  • 兒童

第15章 各地區抗逆轉錄病毒藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章抗逆轉錄病毒藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國抗逆轉錄病毒藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Gilead Sciences, Inc.
    • ViiV Healthcare ULC
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Cipla Limited
    • Aurobindo Pharma Limited
    • Lupin Limited
Product Code: MRR-1A1A064C02F2

The Anti-Retroviral Drugs Market is projected to grow by USD 42.13 billion at a CAGR of 4.75% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 29.05 billion
Estimated Year [2025] USD 30.44 billion
Forecast Year [2032] USD 42.13 billion
CAGR (%) 4.75%

A strategic overview of anti-retroviral therapeutic advances, health system pressures, and practical priorities shaping clinical development and commercial execution

The introductory landscape for anti-retroviral therapeutics must be read through a dual lens of clinical advancement and programmatic delivery. Over the past decade, incremental pharmacologic refinements have transformed antiretroviral therapy from complex multi-pill regimens to simplified combinations and longer-acting modalities, reshaping adherence paradigms and clinical outcomes. Simultaneously, health systems and payers are recalibrating procurement, distribution, and reimbursement models to manage chronic care demands while preserving access and affordability for diverse patient populations. This context demands a strategic synthesis that aligns therapeutic innovation with operational realities.

This executive summary sets out to provide that synthesis. It outlines the major scientific and commercial inflection points affecting product development, regulatory strategy, and supply chain resilience. The narrative connects pharmacologic class dynamics with practical imperatives around formulation, route of administration, and patient-centered delivery. It also examines policy shifts and trade developments that can materially affect cost structures and manufacturing decisions.

Throughout, the focus remains on providing pragmatic insight for stakeholders who must balance clinical efficacy with scalability and access. Decision-makers will find an integrated view that links therapeutic differentiation to real-world deployment, enabling clearer prioritization of investments in research, manufacturing, and commercial execution.

Key scientific, delivery, and commercial inflection points driving the next phase of anti-retroviral therapeutic innovation and health system adoption

The anti-retroviral field is experiencing transformative shifts that extend beyond molecule-level innovation to include delivery, diagnostics, and service design. On the therapeutic front, the maturation of integrase strand transfer inhibitors and the strategic use of combination regimens have redefined efficacy benchmarks, while renewed R&D focus on long-acting parenteral formulations is changing adherence expectations and care pathways. These clinical shifts are occurring in parallel with diagnostics becoming more integrated into treatment algorithms, enabling earlier detection of resistance and more precise switching strategies.

Operationally, manufacturers and health system planners are adapting to a multipronged distribution reality in which hospital-based supply coexists with home care delivery and specialty clinic administration of injectables. This has accelerated investment in cold chain logistics, novel packaging formats, and patient support services to ensure continuity of therapy. Furthermore, regulatory frameworks are evolving to accommodate accelerated pathways for therapies addressing high unmet need and for new formulations intended to improve adherence.

Market access dynamics are concurrently reshaping product strategies. Pricing pressures and greater demand for cost-effective regimens are prompting differential pricing strategies and greater emphasis on lifecycle management. Partnerships between clinical developers, contract manufacturers, and distribution networks are becoming a dominant approach to manage capital intensity while preserving speed to market. Taken together, these shifts signify a landscape where scientific advancement, delivery innovation, and commercial agility jointly determine competitive positioning.

How evolving tariff regimes and trade measures are reshaping supply chain strategy, manufacturing footprints, and procurement decisions for anti-retroviral therapies

The imposition of tariffs and trade measures can create cascading effects across the anti-retroviral supply chain that extend from active pharmaceutical ingredient procurement to finished-dose assembly and distribution. When duties are applied to imported components, manufacturers commonly face higher unit production costs, which can influence decisions about where to site final formulation and packaging operations. In response, some firms accelerate capacity investments closer to end markets, while others renegotiate supplier terms or pursue vertical integration to reduce exposure to cross-border levies.

Tariff-driven cost pressure also amplifies the importance of supplier diversification and contract structure. Companies that maintain multi-sourced API supply chains or that leverage regional manufacturing partners are better positioned to mitigate the immediate impact of trade measures. Contractual clauses that allow for indexation to input costs or that provide for risk-sharing on tariff changes become more important in negotiations with third-party manufacturers and distributors.

Beyond direct cost implications, tariffs influence inventory strategies and working capital management. Organizations often build strategic buffers to smooth short-term supply disruptions and to provide negotiating leverage, but increased inventory levels carry their own financial and logistical costs. Health systems and procurement agencies may respond by emphasizing local procurement and supporting domestic manufacturing initiatives, which can improve supply security but require multi-year commitments and capital allocation. Ultimately, the cumulative impact of trade policy on anti-retroviral therapeutics underscores the need for flexible manufacturing footprints, robust supplier networks, and proactive commercial strategies that anticipate regulatory and tariff volatility.

Comprehensive segmentation intelligence detailing how product types, administration routes, formulation subtypes, care settings, distribution channels, therapy lines, and patient groups drive strategic decisions

Segmentation analysis reveals distinct commercial and clinical implications when the market is viewed through product types, administration routes, formulation specifics, end user settings, distribution channels, therapy line positioning, and patient groups. Based on product type, therapeutic categories such as Ccr5 antagonists, fusion inhibitors, integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors each carry unique resistance profiles, combination potential, and safety considerations that inform formulary preferences and clinical sequencing decisions. Based on route of administration, the dichotomy between oral and parenteral delivery drives differences in adherence support models, administration site requirements, and training needs for providers administering long-acting injectables.

Based on formulation, the landscape encompasses injectable, oral liquid, and oral solid formats. The injectable class requires attention to both intravenous and subcutaneous administration pathways, with implications for clinic capacity and resource allocation. The oral liquid segment divides into solution and suspension presentations, which are critical for pediatric dosing accuracy and palatability. Oral solid forms split into capsule and tablet presentations, with downstream effects on fixed-dose combination strategies and blister or bottle packaging approaches. Based on end user, deployment patterns vary across home care, hospitals, and specialty clinics, each demanding tailored patient support, cold chain logistics where applicable, and different payer interactions.

Based on distribution channel, the roles of hospital pharmacies, online pharmacies, and retail pharmacies shape access, adherence interventions, and inventory policies, while each channel requires distinct regulatory compliance and dispensing workflows. Based on therapy line, first line, salvage therapy, and second line use cases dictate the clinical evidence required for adoption and determine where differentiated products can demonstrate value. Based on patient group, adult and pediatric populations necessitate investment in age-appropriate formulations, dosing regimens, and clinical safety data. Taken together, these segmentation lenses highlight where commercial and clinical priorities intersect, revealing clear levers for product differentiation, formulary positioning, and targeted service design.

Regional market nuances and strategic implications across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory, manufacturing, and access strategies

Regional dynamics exert a powerful influence on regulatory expectations, payer behavior, manufacturing strategy, and distribution design. In the Americas, market dynamics are characterized by a mature procurement ecosystem, growing emphasis on lifecycle management, and a mix of public and private funding mechanisms that shape reimbursement and access. Manufacturers navigating this region must align clinical development plans with payer evidence requirements and design pricing strategies that reflect both urban tertiary care markets and broader public procurement programs.

Europe, Middle East & Africa presents a heterogeneous set of regulatory frameworks and procurement models. Countries within this combined region vary widely in their reliance on centralized tenders, local manufacturing preferences, and capacity to adopt novel delivery formats such as long-acting injectables. This heterogeneity requires segmented regulatory pathways and often necessitates partnerships with regional distributors or contract manufacturers to ensure market entry is commercially viable and operationally sustainable.

Asia-Pacific features a diverse mix of advanced biotech hubs, generics manufacturing centers, and rapidly evolving health systems that increasingly demand cost-effective regimens while also showing strong uptake of novel technologies where reimbursement pathways exist. Manufacturing proximity in this region can offer supply-chain advantages, but regulatory timelines and local clinical data requirements will influence launch sequencing. Across all regions, alignment with public health initiatives, capacity building for specialty clinic administration, and tailored patient support models remain essential to optimize coverage and adherence outcomes.

Strategic corporate approaches and operational capabilities that industry leaders are prioritizing to accelerate pipeline innovation, secure supply, and strengthen market positioning

Companies operating in the anti-retroviral space are adopting a mixture of innovation, partnership, and operational optimization to secure competitive advantage. Across the sector, investment focus is shifting toward platform investments that support long-acting formulations, fixed-dose combinations, and pediatric-appropriate presentations. Firms are increasingly pursuing licensing deals and co-development agreements to accelerate access to complementary technologies such as novel delivery systems and therapeutic drug monitoring tools.

Operationally, leaders are scaling contract manufacturing relationships to manage capital intensity while maintaining control over quality and supply security. Manufacturing strategies increasingly emphasize modular, geographically distributed facilities that can reduce tariff exposure and shorten delivery timelines to large public procurement programs. At the same time, commercial teams are prioritizing differentiated patient support services and digital adherence interventions to protect regimen persistence and to generate real-world evidence that supports reimbursement discussions.

Strategic M&A and selective in-licensing remain central tactics for companies seeking to broaden portfolios rapidly or to acquire complementary capabilities such as pediatric formulation expertise or biologics development experience. The emphasis on lifecycle management, including reformulations and indication expansions, is shaping R&D portfolios to maximize therapeutic longevity while addressing emerging resistance patterns and unmet patient needs.

Actionable, multi-dimensional recommendations for developers and commercial teams to strengthen clinical differentiation, supply resilience, and payer alignment for anti-retroviral offerings

Industry leaders should adopt a layered strategy that simultaneously addresses clinical differentiation, supply resilience, and payer alignment. First, prioritize development of formulations and delivery systems that address the most significant adherence barriers, including investment in long-acting parenteral options and palatable pediatric liquids, while ensuring that clinical development programs generate comparative effectiveness and safety evidence relevant to payers. Second, strengthen supply chain resilience by diversifying API and finished-dose sourcing, negotiating flexible supplier contracts, and evaluating regional manufacturing hubs to mitigate trade-related disruption and tariff exposure.

Third, engage payers and procurement stakeholders early to co-develop value demonstration frameworks that incorporate patient-reported outcomes and real-world adherence data. Fourth, build scalable patient support infrastructure that integrates digital adherence tools, remote monitoring, and training modules for clinicians administering injectables so that uptake is not constrained by service capacity. Fifth, structure commercial launches with channel-specific plans that reflect the unique needs of hospital pharmacies, online pharmacies, and retail dispensaries, and ensure that distribution partners understand cold chain and handling requirements where relevant.

Finally, pursue collaborative arrangements with public health agencies, non-governmental stakeholders, and clinical networks to expedite guideline inclusion and to support implementation studies. These combined actions will help align product innovation with the practical realities of delivery and reimbursement, improving the probability of sustained adoption across diverse care settings.

A transparent, mixed-methods research approach combining expert interviews, regulatory and clinical data review, and scenario analysis to produce actionable, evidence-based insights

The research methodology underpinning this executive summary integrates qualitative and quantitative approaches to ensure findings are robust and actionable. Primary research included semi-structured interviews with clinicians, procurement officers, manufacturing executives, and payers to capture current practice patterns, procurement constraints, and adoption drivers. Secondary research drew on regulatory filings, clinical trial registries, published peer-reviewed literature, and public health guidance documents to validate clinical trends, safety profiles, and regulatory precedents. Data triangulation was used to reconcile divergent perspectives and to ensure conclusions reflect both clinical practice and commercial reality.

Analytical frameworks included therapeutic class mapping, route-of-administration impact assessment, and segmentation crosswalks that linked formulation and distribution considerations to end user requirements. Scenario analysis was applied to explore the operational implications of trade policy shifts and tariff scenarios, focusing on supply chain adjustments rather than market sizing. Limitations include variability in regional regulatory timelines and the evolving nature of long-acting clinical evidence, which means that ongoing surveillance of clinical outcomes and policy shifts is necessary. Where assumptions were made, they were grounded in contemporary published sources and corroborated by expert interviews to preserve analytical integrity.

Concluding synthesis emphasizing the integration of clinical innovation, operational resilience, and payer-focused evidence to translate therapeutic advances into sustained public health impact

In conclusion, the anti-retroviral landscape is being reshaped by synergistic advances in therapeutics, delivery technologies, and service models, all occurring within a policy environment that can materially affect supply chain economics. Clinical innovation in integrase inhibitors, combination strategies, and long-acting formulations offers clear routes to improved adherence and outcomes, but successful commercialization depends on aligning those innovations with pragmatic considerations such as formulation design, administration capacity, and channel-specific distribution strategies.

Trade policy and tariff dynamics further underscore the need for flexible manufacturing strategies and supplier diversification to protect continuity of supply and to manage cost volatility. Segmentation insights emphasize that product success is contingent on precise alignment with patient groups, therapy lines, and end user capabilities, while regional heterogeneity requires tailored regulatory and commercial approaches. For industry leaders, the pathway to durable market impact lies in integrated planning that couples clinical differentiation with operational resilience and payer-focused evidence generation. This integrated approach will be essential to translate scientific advances into measurable public health gains and sustainable commercial outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of long-acting injectable antiretroviral regimens improving patient adherence
  • 5.2. Increasing adoption of two-drug maintenance therapies reducing long-term toxicity risks
  • 5.3. Rapid uptake of generic tenofovir alafenamide formulations lowering treatment costs
  • 5.4. Integration of digital adherence monitoring platforms into HIV care programs
  • 5.5. Expansion of pediatric antiretroviral dosing guidelines to improve child outcomes
  • 5.6. Ongoing development of broadly neutralizing antibody therapies for HIV management
  • 5.7. Regulatory approvals driving uptake of bictegravir-based single-tablet regimens in markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Retroviral Drugs Market, by Product Type

  • 8.1. Ccr5 Antagonists
  • 8.2. Fusion Inhibitors
  • 8.3. Integrase Strand Transfer Inhibitors
  • 8.4. Non-Nucleoside Reverse Transcriptase Inhibitors
  • 8.5. Nucleoside Reverse Transcriptase Inhibitors
  • 8.6. Protease Inhibitors

9. Anti-Retroviral Drugs Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Parenteral

10. Anti-Retroviral Drugs Market, by Formulation

  • 10.1. Injectable
    • 10.1.1. Intravenous
    • 10.1.2. Subcutaneous
  • 10.2. Oral Liquid
    • 10.2.1. Solution
    • 10.2.2. Suspension
  • 10.3. Oral Solid
    • 10.3.1. Capsule
    • 10.3.2. Tablet

11. Anti-Retroviral Drugs Market, by End User

  • 11.1. Home Care
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Anti-Retroviral Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Anti-Retroviral Drugs Market, by Therapy Line

  • 13.1. First Line
  • 13.2. Salvage Therapy
  • 13.3. Second Line

14. Anti-Retroviral Drugs Market, by Patient Group

  • 14.1. Adult
  • 14.2. Pediatric

15. Anti-Retroviral Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Anti-Retroviral Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Anti-Retroviral Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Gilead Sciences, Inc.
    • 18.3.2. ViiV Healthcare ULC
    • 18.3.3. Johnson & Johnson
    • 18.3.4. Merck & Co., Inc.
    • 18.3.5. Bristol-Myers Squibb Company
    • 18.3.6. Teva Pharmaceutical Industries Ltd.
    • 18.3.7. Viatris Inc.
    • 18.3.8. Cipla Limited
    • 18.3.9. Aurobindo Pharma Limited
    • 18.3.10. Lupin Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. ANTI-RETROVIRAL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. ANTI-RETROVIRAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-RETROVIRAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CCR5 ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FUSION INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANTI-RETROVIRAL DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL SOLID, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY THERAPY LINE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PATIENT GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST ANTI-RETROVIRAL DRUGS MARKET SIZE, BY ORAL LIQUID, 2025-2